WalterHealthcareRequest a quote

Oral solids · Contract manufacturing in India

Calcium Carbonate 1250 mg, Copper Sulphate 1.0 mg, Elemental Calcium 500 mg, Elemental Magnesium 1.8 mg, Magnesium Sulphate 10 mg, Vitamin D3 250 IU, Zinc Sulphate 7.5 mg Tablets

Request manufacturing feasibility

Discuss third-party manufacturing of Calcium Carbonate 1250 mg, Copper Sulphate 1.0 mg, Elemental Calcium 500 mg, Elemental Magnesium 1.8 mg, Magnesium Sulphate 10 mg, Vitamin D3 250 IU, Zinc Sulphate 7.5 mg Tablets with Walter Healthcare, India. Share your target market, required tablet count and finished-pack count, packaging and launch timeline for a product-specific quotation.

Catalogue reference
WH-0308
Composition and strength
Calcium Carbonate 1250 mg, Copper Sulphate 1.0 mg, Elemental Calcium 500 mg, Elemental Magnesium 1.8 mg, Magnesium Sulphate 10 mg, Vitamin D3 250 IU, Zinc Sulphate 7.5 mg
Dosage form
Tablets
Indicative administration route
Oral
Therapeutic navigation area
Nutrition & supportive care
Pharmacological class
Nutritional supplement
Manufacturing stream
Non-beta-lactam

Catalogue details support an initial B2B discussion. Walter confirms the applicable unit, current licence scope, formula, target market and commercial feasibility before making a commitment.

Clinical reference

Mechanism and pharmacokinetics.

Explore the published evidence for the ingredients in Calcium Carbonate 1250 mg, Copper Sulphate 1.0 mg, Elemental Calcium 500 mg, Elemental Magnesium 1.8 mg, Magnesium Sulphate 10 mg, Vitamin D3 250 IU, Zinc Sulphate 7.5 mg Tablets. Each reference identifies its source formulation and study context. Ingredient studies describe the named reference product; they do not establish the pharmacokinetics, clinical suitability or bioequivalence of this finished formulation.

How to read our product information and sources ↗

Additional ingredient references still to be verified: Elemental Magnesium. The references below cover only the named ingredients.

Nutrient reference

Vitamin D

Reference for: Vitamin D3. Source presentation: oral nutrient reference. Source route: oral.

Biological role

Vitamin D is converted to active metabolites that support calcium absorption and mineral homeostasis. The physiological role described by NIH includes maintaining bone mineralization; nutrient physiology alone does not establish a treatment claim for a particular supplement.

Absorption and disposition

Vitamin D2 and D3 are absorbed in the small intestine by passive and carrier-mediated processes. Dietary fat enhances absorption, although absorption also occurs without fat. Liver hydroxylation produces 25-hydroxyvitamin D, followed primarily in the kidney by conversion to calcitriol. These steps describe the precursors, not the pharmacokinetics of administered calcitriol.

Nutrient-level summary from NIH. Absorption and disposition describe general oral nutritional physiology, not a pharmacokinetic or bioequivalence study of this finished product.

Source: NIH Office of Dietary Supplements: Vitamin D

Reference accessed .

Nutrient reference

Zinc

Reference for: Zinc Sulphate. Source presentation: oral nutrient reference. Source route: oral.

Biological role

Zinc participates in the catalytic activity of numerous enzymes and contributes to protein and DNA synthesis, cell signaling, cell division and normal immune function.

Absorption and disposition

Zinc balance depends on intestinal absorption, secretion into the gastrointestinal tract and reabsorption. Fractional absorption falls as intake rises. Much of the body zinc pool is in muscle and bone. This nutrient-level reference does not establish the absorption rate or bioavailability of a particular zinc salt or combination.

Nutrient-level summary from NIH. Absorption and disposition describe general oral nutritional physiology, not a pharmacokinetic or bioequivalence study of this finished product.

Source: NIH Office of Dietary Supplements: Zinc

Reference accessed .

Nutrient reference

Calcium

Reference for: Calcium Carbonate; Elemental Calcium. Source presentation: oral nutrient reference. Source route: oral.

Biological role

Calcium provides the mineral structure of bone and teeth. Ionized calcium also participates in muscle contraction, nerve signaling, blood coagulation and hormone secretion.

Absorption and disposition

Intestinal uptake occurs by vitamin-D-dependent active transport and passive diffusion. The absorbed fraction depends on intake and formulation. Calcium carbonate is more dependent on gastric acid than calcium citrate. Most body calcium is held in the skeleton, which is continually remodeled and acts as a reservoir. These nutrient data do not establish this product's bioavailability.

Nutrient-level summary from NIH. Absorption and disposition describe general oral nutritional physiology, not a pharmacokinetic or bioequivalence study of this finished product.

Source: NIH Office of Dietary Supplements: Calcium

Reference accessed .

Nutrient reference

Copper

Reference for: Copper Sulphate. Source presentation: oral nutrient reference. Source route: oral.

Biological role

Copper is a cofactor in enzymes involved in energy production, iron metabolism, connective-tissue synthesis and neurotransmitter processing. Copper-containing superoxide dismutases participate in defense against oxidative damage.

Absorption and disposition

Dietary copper is absorbed primarily in the upper small intestine. Ceruloplasmin carries most plasma copper. Intestinal uptake and liver secretion into bile regulate copper balance; bile is the major elimination route and urinary loss is smaller. This general nutrient disposition does not establish salt-specific bioavailability.

Nutrient-level summary from NIH. Absorption and disposition describe general oral nutritional physiology, not a pharmacokinetic or bioequivalence study of this finished product.

Source: NIH Office of Dietary Supplements: Copper

Reference accessed .

Nutrient reference

Magnesium

Reference for: Magnesium Sulphate. Source presentation: oral nutrient reference. Source route: oral.

Biological role

Magnesium supports numerous enzyme systems in energy metabolism, protein synthesis and nucleic-acid synthesis. It also participates in ion transport needed for nerve and muscle function.

Absorption and disposition

The NIH review estimates that about 30–40% of dietary magnesium is usually absorbed. Supplemental absorption varies with the compound and its solubility. Most body magnesium is in bone or soft tissue; the kidneys regulate balance by changing urinary excretion. These oral nutrient data are not injectable-magnesium pharmacokinetics.

Nutrient-level summary from NIH. Absorption and disposition describe general oral nutritional physiology, not a pharmacokinetic or bioequivalence study of this finished product.

Source: NIH Office of Dietary Supplements: Magnesium

Reference accessed .

Editorial development perspective

What deserves attention in this formulation.

These notes use the catalogue composition and presentation to frame a technical discussion. They are planning considerations, not tested properties or clinical findings for this product.

The clinical references on this page cover only their named ingredients. These development notes do not resolve the remaining clinical-reference gaps.

About these development notes and source limitations ↗

Balance tablet performance and processability

Listed presentation: Tablets.

Use early development batches to compare blend flow, compression behaviour, tablet strength and the appropriate release test. A harder tablet or a faster disintegration result is not, by itself, a complete product specification. Set priorities around the intended presentation, then check that the chosen process can reproduce them at the proposed scale.

Reconcile the declared amount with the input material

Catalogue wording: “Elemental”.

Put the declared active or elemental amount and the quantity of its supplied compound on the same calculation sheet. Check the equivalence basis against the raw-material assay and the proposed label wording. Keep calculations explicit when comparing suppliers so that a change in grade does not silently change the intended amount per unit.

Carry the exact ingredient form into development

Catalogue wording: “Sulphate”.

Use the named ingredient form when requesting material specifications and comparing possible suppliers. Resolve assay, water-content and strength-equivalence conventions before converting a formula into batch quantities. A similarly named salt or hydrate should be assessed as a distinct material choice rather than introduced through a naming shortcut.

Suggested starting point

A practical starting point is to reconcile the declared amount with the input material. For this tablets brief, agree the target characteristics and a short set of measurable development questions before comparing prototypes or supplier proposals. Keep unresolved clinical claims outside the product specification until supporting evidence is available.

Discuss this product brief

Manufacturing & packaging brief

Plan the tablet presentation.

Use this preparation guide for Calcium Carbonate 1250 mg, Copper Sulphate 1.0 mg, Elemental Calcium 500 mg, Elemental Magnesium 1.8 mg, Magnesium Sulphate 10 mg, Vitamin D3 250 IU, Zinc Sulphate 7.5 mg Tablets. These are the decisions to resolve with the technical team before a site, process and commercial scope are confirmed.

Presentation & formulation

Define release type, coating, scoring and any reference-product requirements. Keep each strength and presentation as a separate item in the brief.

Quality & technical transfer

Agree the product specification, analytical methods and applicable dissolution or disintegration requirements. Identify the formula and process information available for transfer.

Review the technical documents

Packaging configuration

Compare the proposed blister, strip or bottle with the formulation and its protection requirements. Specify tablets per primary pack and primary packs per carton.

Explore packaging options

Details to confirm for this record

Full composition
Keep all named components and their individual amounts together in the specification. Ingredient substitutions, omissions and changed ratios require a separate formula and permission review.
Salt and strength wording
Confirm whether the stated amount refers to the named salt, hydrate or equivalent active moiety. Use the agreed expression consistently in the specification, quotation and artwork.

Quantities, MOQ & lead time

For Calcium Carbonate 1250 mg, Copper Sulphate 1.0 mg, Elemental Calcium 500 mg, Elemental Magnesium 1.8 mg, Magnesium Sulphate 10 mg, Vitamin D3 250 IU, Zinc Sulphate 7.5 mg Tablets (WH-0308), state the tablet count and finished-pack count, target market and reorder forecast. MOQ and lead time depend on the assessed formula, process, components, testing and project readiness; request those terms in writing.

Discuss this manufacturing brief

Explore the context

Build the right manufacturing brief.

Dosage-form capabilitiesOral solidsTherapeutic navigationNutrition & supportive careFull catalogueSearch other compositions

Related catalogue records

Grouped by catalogue navigation labels, not by therapeutic interchangeability or clinical recommendation.

Common questions

Before you request a quotation.

Calcium Carbonate 1250 mg, Copper Sulphate 1.0 mg, Elemental Calcium 500 mg, Elemental Magnesium 1.8 mg, Magnesium Sulphate 10 mg, Vitamin D3 250 IU, Zinc Sulphate 7.5 mg Tablets

What is listed in the catalogue?

The catalogue lists Calcium Carbonate 1250 mg, Copper Sulphate 1.0 mg, Elemental Calcium 500 mg, Elemental Magnesium 1.8 mg, Magnesium Sulphate 10 mg, Vitamin D3 250 IU, Zinc Sulphate 7.5 mg as tablets in its nutrition & supportive care navigation area and non-beta-lactam manufacturing stream.

How do you confirm manufacturing availability?

Send Walter your requirement for Calcium Carbonate 1250 mg, Copper Sulphate 1.0 mg, Elemental Calcium 500 mg, Elemental Magnesium 1.8 mg, Magnesium Sulphate 10 mg, Vitamin D3 250 IU, Zinc Sulphate 7.5 mg Tablets. The team reviews the applicable product permission and unit, formulation and equipment fit, testing, packaging and production schedule before confirming the manufacturing scope in writing. Request the relevant product and facility documents with your enquiry.

What do I need for a quotation?

Share the exact composition and strength, tablets presentation, target market, initial quantity, preferred pack and timing. Identify whether this is a new product, development brief or transfer.

The quotation must confirm MOQ, inclusions, prerequisites and lead time for the proposed product and site.

What is needed for Indian and export markets?

For India, share the intended brand or institutional supply requirement, pack sizes, initial order quantity and artwork needs for Calcium Carbonate 1250 mg, Copper Sulphate 1.0 mg, Elemental Calcium 500 mg, Elemental Magnesium 1.8 mg, Magnesium Sulphate 10 mg, Vitamin D3 250 IU, Zinc Sulphate 7.5 mg Tablets. Confirm the applicable product permission, manufacturing unit and labelling requirements with the team.

For export, identify each destination country, proposed pack, language and registration or dossier requirements. Ask which product-specific quality and stability documents are available. Container compatibility and destination-market requirements need review; a catalogue record does not establish export registration or a shelf-life commitment.

How do I submit my enquiry?

Use the product-specific enquiry button to carry this composition and dosage form into the form. After a successful submission, a receipt reference confirms that your brief has been saved for review. Use the RFQ checklist to prepare the remaining details.

Technical document review

Which documents can I ask Walter to review?

Ask about manufacturing and packing records, specifications, analytical methods, Certificates of Analysis (COA), stability evidence, the Process Validation Protocol (PVP) and Process Validation Report (PVR). The wider checklist below covers supplier qualification, technical transfer and ongoing supply.

View the full document checklist 14 review areas
Site, licence and audit scope
Manufacturing licence, applicable product permissions, GMP certificates, Site Master File, supplier-qualification questionnaire and relevant audit responses.
Manufacturing, packing and batch release
Master Formula Record (MFR), master packing instructions, Batch Manufacturing Record (BMR), Batch Packing Record (BPR), reconciliation and authorised release records.
Process validation and continued verification
Process Validation Protocol (PVP), Process Validation Report (PVR), process performance qualification documents and continued process verification trends.
Equipment, facilities and utilities
Validation Master Plan (VMP), user requirements, DQ/IQ/OQ/PQ records, calibration and maintenance evidence for relevant equipment and utilities.
Cleaning, carryover and hold times
Cleaning Validation Protocol (CVP), Cleaning Validation Report (CVR), residue limits, recovery studies and applicable clean, dirty and process hold-time studies.
Specifications and analytical evidence
Specifications, Method of Analysis (MOA), Standard Testing Procedure (STP), Certificates of Analysis (COA), analytical validation, verification and method-transfer records.
Stability, packaging and transport
Stability protocols/reports, ongoing stability commitments, pack specifications, approved artwork, compatibility and applicable packaging or transport studies.
Development and technology transfer
Development report, technology-transfer protocol/report, gap assessment, control strategy, critical quality attributes and critical process parameters.
Quality reviews, investigations and changes
Product Quality Review (PQR) / Annual Product Review (APR), deviations, CAPA, change control, OOS/OOT trends, complaints, recalls and relevant SOP/training records.
Material suppliers and impurity risks
API/excipient supplier qualification, traceability, material COAs, relevant origin declarations and impurity risk assessments with supporting tests.
Sterile-product evidence, where applicable
Contamination Control Strategy (CCS), media-fill/aseptic simulation reports, sterilisation and filtration validation, environmental monitoring, sterility/endotoxin and container-closure integrity evidence.
Computerised systems and data integrity
Computerised-system validation, access controls, audit-trail review, backup/restore checks and relevant data-integrity procedures.
Market-specific regulatory support
Applicable dossier sections, API master-file/CEP support, bioequivalence or biowaiver evidence and Certificate of a Pharmaceutical Product (CPP/CoPP), where required and available.
Quality agreement and access arrangements
Quality/technical agreement covering responsibilities, release, changes, subcontracting, investigations, complaints, recalls, audits and document access.

Agree the list for the exact product, site, process, pack, market and project stage. QA confirms what exists, applies and may be shared; some records may require an NDA, redaction or controlled review. See document definitions and review guidance.

Important qualification

This B2B catalogue record is not proof of current approval or confirmation that Calcium Carbonate 1250 mg, Copper Sulphate 1.0 mg, Elemental Calcium 500 mg, Elemental Magnesium 1.8 mg, Magnesium Sulphate 10 mg, Vitamin D3 250 IU, Zinc Sulphate 7.5 mg Tablets is available for sale. It is not prescribing information or patient advice. Any Drugs Rules status, current approval, exemption, applicable unit, licence scope, formulation, claims, brand use, destination-market registration and commercial feasibility require documentary verification and Walter's written confirmation. Read the full regulatory disclaimer.

Composition and classification are taken from Walter's product catalogue. The manufacturing guide helps buyers prepare a technical brief. Clinical references, where shown, describe the cited product and study. Manufacturing guide updated .